Pharmafile Logo
Pharmafocus logo
Advanced Search

Bluebird Bio

Showing 10 posts of 10 posts found.

bluebird_bio_external_durham_nc_manufacturing

FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin

February 24, 2021
Research and Development Bluebird Bio, FDA, sickle cell disease

The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …

News
bluebird_bio_external_durham_nc_manufacturing

Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy

September 23, 2019
Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma

Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …

News

EMA approves Bluebird Bio’s gene therapy Zynteglo

June 4, 2019
Manufacturing and Production Bluebird Bio, European comission, gene therapy, health, pharma

The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo. The Massachusetts-based firm’s one time …

News
credit_-_daniel_leal-olivas-afp

CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia

April 1, 2019
Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia

Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …

News
8b437d43644106a4fb11aa4292aa6fbd_1

Working Life: Nicola Redfern, UK General Manager, bluebird bio

February 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, Interview, Working Life, pharma

How did you find your way into the pharma industry? Was it always an aspiration of yours? My mum worked …

Feature
nicola_redfern

bluebird bio reveals new UK General Manager

January 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, appointment, pharma

bluebird bio, a US-based gene therapy biotech with a focus on cancer and severe genetic conditions,  has named Nicola Redfern …

Appointment
shutterstock_273326141

Medigene and bluebird bio expand immunotherapy partnership to $1.5bn

May 14, 2018
Research and Development, Sales and Marketing Bluebird Bio, Cancer, Medigene, pharma

Medigene has announced that it has bolstered the existing partnership it has in place with US firm bluebird bio, originally …

News
handshake2

bluebird backs own CAR-T prospect, takes option to co-develop with Celgene

March 29, 2018
Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016
Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …

News

Gene therapy advance hailed for thalassemia

September 16, 2010
Research and Development Bluebird Bio, gene therapy, thalassemia

A new gene therapy for one of the most frequently inherited genetic disorders has produced promising results. The trial by …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024